Recon: Neurocrine’s schizophrenia drug posts mixed results in Phase 2 study; BioMarin to lay off 225 of its staff
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States